Highlights Precigen, Inc.

Equities

PGEN

US74017N1054

Delayed Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
1.47 ^USD	-1.34%		-5.16%	+9.70%

Jul. 01	Precigen, Inc.(NasdaqGS:PGEN) added to Russell 3000 Growth Index	CI
Jul. 01	Precigen, Inc.(NasdaqGS:PGEN) added to Russell Microcap Growth Index	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Precigen Share Rise After Recurrent Respiratory Papillomatosis Study Shows 51% of Patients Surgery Free	Jun. 03	MT
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response	Jun. 03	CI
Precigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M	May. 14	MT
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	Apr. 24	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	Jan. 16	CI
Precigen Q3 Net Loss Widens, Revenue Falls	Nov. 09	MT
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (PGEN) PRECIGEN Posts Q3 Revenue $1.4M	Nov. 09	MT
Earnings Flash (PGEN) PRECIGEN Reports Q2 Revenue $1.8M, vs. Street Est of $2.2M	23-08-09	MT
Precigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval	23-08-09	CI
Precigen Gets US FDA Grants Breakthrough Therapy Designation to PRGN-2012 for Recurrent Respiratory Papillomatosis Treatment	23-06-20	MT
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerseâ„¢ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	23-06-20	CI
Precigen Unveils Positive Phase 1 Data From Advanced Stage Platinum Resistant Ovarian Cancer Patients	23-06-05	MT
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients	23-06-05	CI
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers	23-06-03	CI
Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer	23-05-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Precigen, Inc.

Equities

PGEN

US74017N1054

Highlights

Filters